Generic diabetes drug candidate put to the test in healthy volunteers

NCT ID NCT07691177

Completed Disease control Sponsor: Humanis Saglık Anonim Sirketi Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial investigates whether a generic tablet containing imeglimin hydrochloride works the same way in the body as the brand-name diabetes drug Twymeeg. Healthy adults aged 18 to 45 take a single dose of each version under fasting conditions, and researchers compare how much drug gets into the bloodstream and how long it stays. The goal is to see if the generic can be a safe, effective, and more affordable alternative for managing type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Imeglimin hydrochloride
What this could lead to: If the generic tablet proves equivalent, it could provide a lower-cost treatment option for people with type 2 diabetes.
What could go wrong: This is an early-phase study in healthy volunteers, not patients. Even if bioequivalence is shown, it does not guarantee the drug's effectiveness or safety in treating diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Show contact details

Locations

Veeda Clinical Research Ltd.

Gujrāt, Ahmedabad, 380 015, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.